An Updated Analysis Evaluating Skeletal Related Events (Sres) In Ctrial-Ie 13-21: Phase Ii Trial Of Radium-223 (R223) In Combination With Enzalutamide (Enza) For Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
JOURNAL OF CLINICAL ONCOLOGY（2019）
Key words
prostate cancer,phase ii ctrial-ie,castration-resistant
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined